Abivax SA (ABVX) Stock Price & How to Invest
Short answer
ABVX is the U.S.-listed ADR of Abivax, a clinical-stage biotech whose value rests almost entirely on obefazimod, an oral drug that just delivered positive Phase 3 results in ulcerative colitis, so investing here means owning a single-asset, binary regulatory story rather than an established earnings business.
ABVX stock price
As of 2026-07-02, Abivax SA (ABVX) last closed at $144.65, up 1717.2% over the past year. Over the past 52 weeks it has traded between $7.75 and $145.31.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Abivax SA's investor relations page. Walnut is informational, not investment advice.
What does Abivax SA (ABVX) do?
Abivax SA is a French clinical-stage biopharmaceutical company listed on Nasdaq via a sponsored ADR (ABVX). Its lead and effectively sole value driver is obefazimod (formerly ABX464), a first-in-class oral miR-124 enhancer being developed for inflammatory bowel disease. In 2025 and 2026 the pivotal Phase 3 ABTECT program in moderate-to-severe ulcerative colitis reported positive results across both induction trials and the maintenance trial, with the 50 mg dose showing clinical remission around 51% at Week 44 versus roughly 10% for placebo. Management has guided toward a U.S. FDA new drug application filing in late 2026, with a Phase 2b Crohn's disease readout expected around mid-2027.
The investment picture is a classic late-stage biotech binary. Abivax has negligible product revenue and posts large ongoing net losses because it is spending heavily on trials, which is normal for a company at this stage and not by itself a red flag. The shares are highly event-driven: the stock roughly moved from the mid-$90s to the mid-$140s around the mid-2026 Phase 3 data, and an upsized ~$800M ADS raise at $125 extended the projected cash runway into 2029. Upside depends on FDA approval and a successful launch (or a partnership/acquisition), while the main downside risks are regulatory setbacks, competition, and shareholder dilution.
What's driving Abivax SA (ABVX)?
1. Positive Phase 3 obefazimod data
Both ABTECT induction trials and the maintenance trial met their primary endpoints, with the 50 mg dose reaching roughly 51% clinical remission at Week 44 versus about 10% on placebo. The data positioned obefazimod as a competitive oral option in ulcerative colitis and drove a sharp re-rating of the shares in mid-2026.
2. Path to an FDA filing
Management has guided toward submitting a U.S. new drug application for obefazimod in ulcerative colitis around Q4 2026. A regulatory filing and any eventual approval would be the key milestones that convert a clinical-stage story into a potential commercial one.
3. Pipeline expansion into Crohn's disease
Beyond ulcerative colitis, Abivax is running a Phase 2b induction study of obefazimod in Crohn's disease, with data guided to around mid-2027. A second large indication would broaden the addressable market for the same molecule and diversify the single-asset dependence somewhat.
4. Strengthened balance sheet
An upsized, oversubscribed U.S. ADS offering priced at $125 raised roughly $800M and extended the projected cash runway into 2029. That funding is meant to carry the company through the FDA filing and potential U.S. commercialization without an immediate need to raise again.
What are the risks to Abivax SA (ABVX)?
As a single-asset biotech, essentially all of Abivax's value depends on obefazimod, so a regulatory rejection, a delay, or a negative safety finding could sharply reduce the shares. Malignancy signals at the 50 mg dose have been a focal regulatory question, even though integrated safety data reported rates in line with background disease incidence. The ulcerative colitis market is crowded with established therapies such as Rinvoq, Skyrizi, Zeposia, and Entyvio, so commercial success is not guaranteed even after approval. The company generates negligible revenue and large net losses, and repeated equity raises have diluted shareholders. Approval, launch execution, and any partnership or acquisition outcome all remain uncertain.
How is Abivax SA (ABVX) valued? (approximate, July 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Abivax SA's investor relations page or your broker.
- Market cap: ~$7-8B
- Product revenue (TTM): ~negligible (pre-commercial)
- Net loss (FY2025): ~EUR 336M
- R&D expense (FY2025): ~EUR 178M
- Cash and investments: ~EUR 490M (Q1 2026), boosted by ~$800M raise
- Cash runway: ~into 2029 after mid-2026 raise
Abivax has effectively no product revenue and posts large net losses, which is normal for a clinical-stage biotech funding pivotal trials rather than a warning sign on its own. Traditional earnings multiples do not apply; the market instead values the probability-weighted potential of obefazimod reaching and selling in the market. The mid-2026 capital raise materially extended the runway and reduced near-term financing risk.
Who competes with Abivax SA (ABVX)?
Oral small-molecule IBD drugs
Obefazimod's most direct competition as an oral therapy comes from JAK inhibitors such as AbbVie's Rinvoq (upadacitinib) and Pfizer's Xeljanz (tofacitinib), plus S1P modulators like Bristol Myers Squibb's Zeposia (ozanimod) and Pfizer's Velsipity. Abivax's pitch is competitive efficacy with a lighter monitoring burden than S1P and JAK options.
Biologic IBD therapies
Injected and infused biologics dominate treatment of moderate-to-severe ulcerative colitis, including AbbVie's Humira and Skyrizi, Takeda's Entyvio, and Johnson & Johnson's Stelara and Tremfya. These set the efficacy and reimbursement benchmarks any new entrant must clear.
Other clinical-stage IBD developers
Numerous biotech and pharma programs are pursuing novel oral and biologic mechanisms for ulcerative colitis and Crohn's disease. As a first-in-class miR-124 enhancer, Abivax differentiates on mechanism, but faces the risk that competing pipeline assets reach the market with comparable or better profiles.
How to invest in Abivax SA (ABVX)
There are three common ways to get ABVX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so ABVX sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where ABVX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Abivax SA (ABVX)
Abivax is a late-stage, one-drug biotech where the entire investment case hinges on obefazimod reaching the market, funded by a recently extended cash runway.
More on Abivax SA (ABVX)
Whether ABVX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ABVX a buy?, and where the stock could go from here in the ABVX stock forecast.
For income investors, whether ABVX pays a dividend and how the payout looks is covered in does ABVX pay a dividend?
Build a basket around ABVX with Walnut
Use Abivax SA as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does Abivax (ABVX) do?
+
Abivax is a clinical-stage biopharmaceutical company developing obefazimod, an oral drug for inflammatory bowel disease. It is not yet selling a marketed product, so its value is tied to advancing obefazimod through trials and regulatory review.
Why does ABVX have almost no revenue?
+
Abivax is pre-commercial, meaning its lead drug is not yet approved for sale. Negligible revenue and large net losses are typical for a clinical-stage biotech that is spending heavily on Phase 3 trials rather than generating product sales.
What is obefazimod?
+
Obefazimod (formerly ABX464) is Abivax's lead candidate, a first-in-class oral miR-124 enhancer being developed for ulcerative colitis and Crohn's disease. It is the company's main value driver and the focus of its Phase 3 program.
How did the Phase 3 ulcerative colitis trials go?
+
The Phase 3 ABTECT induction and maintenance trials reported positive results, with the 50 mg dose reaching roughly 51% clinical remission at Week 44 versus about 10% for placebo. The data drove a sharp re-rating of the stock in mid-2026.
When could obefazimod reach the market?
+
Management has guided toward filing a U.S. FDA new drug application around late 2026. Any approval and launch would come later, and timing depends on the FDA review, so the path to commercialization remains uncertain.
Does Abivax have enough cash?
+
As of early 2026 Abivax reported roughly EUR 490M in cash and investments, and an upsized ~$800M ADS raise at $125 extended the projected runway into 2029. That funding is intended to cover the FDA filing and potential U.S. launch.
Who competes with obefazimod?
+
In ulcerative colitis it would compete with oral drugs like Rinvoq, Xeljanz, Zeposia, and Velsipity, and with biologics such as Humira, Skyrizi, Entyvio, and Stelara. The market is crowded, so commercial success is not guaranteed even after approval.
What are the main risks with ABVX?
+
As a single-asset biotech, its value depends almost entirely on obefazimod, so a regulatory rejection, delay, safety concern, or weak launch could sharply hurt the shares. Repeated equity raises have also diluted shareholders. Walnut is not an investment adviser, and this is for information only.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Abivax SA's investor relations page or your broker before making investment decisions.